OKYONasdaqBiological Products, (No Diagnostic Substances)

OKYO Pharma Ltd

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 20, 2026

$1.40−0.01 (-0.71%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

OKYO Pharma Ltd income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31	FY 2020 2020-03-31
Research & Development	1.81	2.25	8.24	6.34	1.61	0.35	0.52
Operating Expenses	6.69	4.84	7.51	6.85	4.61	3.02	1.02
Interest Expense	0.47	0.88	1.05	0.10	–	0.00	0.00
Interest & Investment Income	0.03	0.01	–	–	–	–	0.05
Pretax Income	-8.94	-7.97	-17	-13	-6.22	-3.38	-1.62
Income Tax Expense	-0.01	3.26	-0.02	0.01	0.79	0.02	0.08
Net Income incl. Noncontrolling Interests	-8.95	-4.71	-17	-13	-5.43	-3.35	-1.54
Net Income to Common	-8.95	-4.71	-17	-13	-5.43	-3.35	-1.54
EPS (Basic)(per share)	-0.24	-0.12	-0.57	-0.61	-0.36	-0.32	–
EPS (Diluted)(per share)	-0.24	-0.12	-0.57	-0.61	-0.36	-0.32	–
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	979	673	595
Shares Outstanding (Diluted, Weighted)(shares)	–	–	–	–	979	673	595

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: –

Financial strength

Current ratio: 2.43
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 168.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –